Keyword: PD-1

Opdivo

2. Opdivo

Opdivo was the first drug in the PD-1/PD-L1 inhibitor class to reach the market after its approval in Japan in 2014, but then followed Merck’s Keytruda by several months in winning an FDA approval—and the two drugs have seesawed for dominance ever since.